Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2720-2733

  Babu, Anish ^a,b   Wang, Qi ^a,b   Muralidharan, Ranganayaki ^a,b   Shanker, Manish ^c,f   Munshi, Anupama ^b,d   Ramesh, Rajagopal ^a,b,e  

^a Biomedical Research Center   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

^f UNIVERSITY OF TEXAS DENTAL BRANCH AT HOUSTON   (United States)

Author keywords

chitosan; cisplatin; drug resistance; multifunctional nanoparticle; ovarian cancer; P62 SQSTM1; polylactic acid; proteasome; 5

Indexed keywords

CHITOSAN; CISPLATIN; NANOPARTICLE; PLASMID DNA; POLYLACTIC ACID; PROTEASOME; PROTEASOME SUBUNIT BETA5; PROTEIN P62; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLUORESCAMINE; LACTIC ACID; P62 PROTEIN, HUMAN; POLYMER; RNA BINDING PROTEIN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL KILLING; CHEMOSENSITIZATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SENSITIVITY; GENE SILENCING; HUMAN; HUMAN CELL; HYDRODYNAMICS; IC 50; IN VITRO GENE TRANSFER; MOLECULAR STABILITY; MORPHOLOGY; NONVIRAL GENE DELIVERY SYSTEM; OVARIAN CANCER CELL LINE; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; SPECTROPHOTOMETRY; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DRUG RESISTANCE; FEMALE; IC50; METABOLISM; NANOMEDICINE; OVARIAN NEOPLASMS; PLASMID; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCAMINE; HUMANS; INHIBITORY CONCENTRATION 50; LACTIC ACID; NANOMEDICINE; NANOPARTICLES; OVARIAN NEOPLASMS; PARTICLE SIZE; PLASMIDS; POLYMERS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 84905485892     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500259e     Document Type: Article

References (56)

1. Romanini, A.; Tanganelli, L.; Carnino, F.; Fanucchi, A.; Lionetto, R.; Pastorino, S.; Cosio, S.; Gadducci, A.; Conte, P. F. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients Gynecol. Oncol. 2003, 89, 354-359
2. Sorbe, B.; Graflund, M.; Horvath, G.; Swahn, M.; Boman, K.; Bangshoj, R.; Lood, M.; Malmstrom, H. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer Int. J. Gynecol. Cancer 2012, 22, 47-53
3. Vasey, P. A.; Atkinson, R.; Coleman, R.; Crawford, M.; Cruickshank, M.; Eggleton, P.; Fleming, D.; Graham, J.; Parkin, D.; Paul, J.; Reed, N. S.; Kaye, S. B. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br. J. Cancer 2001, 84, 170-178
4. Martin, L. P.; Hamilton, T. C.; Schilder, R. J. Platinum resistance: the role of DNA repair pathways Clin. Cancer Res. 2008, 14, 1291-1295
5. Kikuchi, Y.; Iwano, I.; Miyauchi, M.; Kita, T.; Oomori, K.; Kizawa, I.; Sugita, M.; Tenjin, Y. The mechanism of acquired resistance to cisplatin by a human ovarian cancer cell line JPN J. Cancer Res. 1988, 79, 632-635
6. Yang, X.; Fraser, M.; Moll, U. M.; Basak, A.; Tsang, B. K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway Cancer Res. 2006, 66, 3126-3136
7. Shen, D. W.; Pouliot, L. M.; Hall, M. D.; Gottesman, M. M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol. Rev. 2012, 64, 706-721
8. Wang, J.; Zhou, J. Y.; Wu, G. S. Bim protein degradation contributes to cisplatin resistance J. Biol. Chem. 2011, 286, 22384-22392
9. Yang, Z. J.; Chee, C. E.; Huang, S.; Sinicrope, F. A. The role of autophagy in cancer: therapeutic implications Mol. Cancer Ther. 2011, 10, 1533-1541
10. Chen, Y.; Klionsky, D. J. The regulation of autophagy-unanswered questions J. Cell Sci. 2011, 124, 161-170
11. Boya, P.; Reggiori, F.; Codogno, P. Emerging regulation and functions of autophagy Nat. Cell Biol. 2013, 15, 713-720
12. Bjorkoy, G.; Lamark, T.; Pankiv, S.; Overvatn, A.; Brech, A.; Johansen, T. Monitoring autophagic degradation of p62/SQSTM1 Methods Enzymol. 2009, 452, 181-197
13. Puissant, A.; F, N.; Auberger, P. When autophagy meets cancer through p62/SQSTM1 Am. J. Cancer Res. 2012, 2, 397-413
14. Johansen, T.; Lamark, T. Selective autophagy mediated by autophagic adapter proteins Autophagy 2011, 7, 279-296
15. Yu, H.; Su, J.; Xu, Y.; Kang, J.; Li, H.; Zhang, L.; Yi, H.; Xiang, X.; Liu, F.; Sun, L. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins Eur. J. Cancer 2011, 47, 1585-1594
16. Rolland, P.; Madjd, Z.; Durrant, L.; Ellis, I. O.; Layfield, R.; Spendlove, I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease Endocr.-Relat. Cancer 2007, 14, 73-80
17. Kitamura, H.; Torigoe, T.; Asanuma, H.; Hisasue, S. I.; Suzuki, K.; Tsukamoto, T.; Satoh, M.; Sato, N. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue Histopathology 2006, 48, 157-161
18. Qian, H. L.; Peng, X. X.; Chen, S. H.; Ye, H. M.; Qiu, J. H. P62 Expression in primary carcinomas of the digestive system World J. Gastroenterol. 2005, 11, 1788-1792
19. Thompson, H. G.; Harris, J. W.; Wold, B. J.; Lin, F.; Brody, J. P. P62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells Oncogene 2003, 22, 2322-2333
20. Lamark, T.; Johansen, T. Aggrephagy: selective disposal of protein aggregates by macroautophagy Int. J. Cell Biol. 2012, 2012, 736905
21. Voges, D.; Zwickl, P.; Baumeister, W. The 26S proteasome: a molecular machine designed for controlled proteolysis Annu. Rev. Biochem. 1999, 68, 1015-1068
22. Oerlemans, R.; Franke, N. E.; Assaraf, Y. G.; Cloos, J.; van Zantwijk, I.; Berkers, C. R.; Scheffer, G. L.; Debipersad, K.; Vojtekova, K.; Lemos, C.; van der Heijden, J. W.; Ylstra, B.; Peters, G. J.; Kaspers, G. L.; Dijkmans, B. A.; Scheper, R. J.; Jansen, G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood 2008, 112, 2489-2499
23. Wang, X. J.; Yu, J.; Wong, S. H.; Cheng, A. S.; Chan, F. K.; Ng, S. S.; Cho, C. H.; Sung, J. J.; Wu, W. K. A novel crosstalk between two major protein degradation systems: Regulation of proteasomal activity by autophagy Autophagy 2013, 9, 1500-1508
24. Lilienbaum, A. Relationship between the proteasomal system and autophagy Int. J. Biochem. Mol. Biol. 2013, 4, 1-26
25. Ding, W. X.; Ni, H. M.; Gao, W.; Yoshimori, T.; Stolz, D. B.; Ron, D.; Yin, X. M. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability Am. J. Pathol. 2007, 171, 513-24
26. Viiri, J.; Hyttinen, J. M.; Ryhanen, T.; Rilla, K.; Paimela, T.; Kuusisto, E.; Siitonen, A.; Urtti, A.; Salminen, A.; Kaarniranta, K. p62/sequestosome 1 as a regulator of proteasome inhibitor-induced autophagy in human retinal pigment epithelial cells Mol. Vis. 2010, 16, 1399-1414
27. Shanker, M.; Began, G.; Scott, A. W.; Miranda, D.; Jones, L.; Roth, J. A.; Ramesh, R. Proteasome and Drug Resistance: Identification of a Novel Mechanism for the beta-5 subunit of the 20S Proteasome in Regulating Cisplatin Resistance. In Proceedings of the 100th Annual Meeting of the American Association of Cancer Research, 2009 April 18-22; Denver, CO; AACR: Philadelphia, PA; 2009; Abstract nr 3879.
28. Fessi, H.; P, F.; D, J. P.; Ammoury, N.; Benita, S. Nanocapsule formation by interfacial polymer deposition following solvent displacement Int. J. Pharm. 1989, 55, R1-R4
29. Udenfriend, S.; Stein, S.; Böhlen, P.; Dairman, W.; Leimgruber, W.; Weigele, M. Fluorescamine. A reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range Science 1972, 178, 871-872
30. Corsi, K.; Chellat, F.; Yahia, L. H.; Fernandes, J. C. Mesenchymal stem cells, MG 63 and HEK 293 transfection using chitosan-DNA nanoparticles Biomaterials 2003, 24, 1255-1264
31. Vasiliev, A. N.; Gulliver, E. A.; Khinast, J. G.; Riman, R. E. Highly dispersible polymer-coated silver Nanoparticles Surf. Coat. Technol. 2009, 203, 2841-2844
32. Ambjørn, M.; Dubreuil, V.; Miozzo, F.; Nigon, F.; Møller, B.; Issazadeh-Navikas, S.; Berg, J.; Lees, M.; Sap, J. A Loss-of-Function Screen for Phosphatases that Regulate Neurite Outgrowth Identifies PTPN12 as a Negative Regulator of TrkB Tyrosine Phosphorylation PLoS One 2013, 8, e65371 10.1371/journal.pone.0065371
33. Yokoyama, T.; Tam, J.; Kuroda, S.; Scott, A. W.; Aaron, J.; Larson, T.; Shanker, M.; Correa, A. M.; Kondo, S.; Roth, J. A.; Sokolov, K.; Ramesh, R. EGFR-Targeted Hybrid Plasmonic Magnetic Nanoparticles Synergistically Induce Autophagy and Apoptosis in Non-Small Cell Lung Cancer Cells PLoS One 2011, 6, e25507 10.1371/journal.pone.0025507
34. Zhang, X.; Yashiro, M.; Qiu, H.; Nishi, T.; Matsuzaki, T.; Hirakawa, K. Establishment and characterization of multi drug resistant gastric cancer cell lines Anticancer Res. 2010, 30, 915-922
35. Pittella, F.; Zhang, M.; Lee, Y.; Kim, H. J.; Tockary, T.; Osada, K.; Ishii, T.; Miyata, K.; Nishiyama, N.; Kataoka, K. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity Biomaterials 2011, 32, 3106-3114
36. Huang, Q.; Figueredo-Pereira, M. E. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications Apoptosis 2010, 15, 1292-1311
37. Chondrogianni, N.; Stratford, F. L.; Trougakos, I. P.; Friguet, B.; Rivett, A. J.; Gonos, E. S. Central Role of the Proteasome in Senescence and Survival of Human Fibroblasts-Induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation J. Biol. Chem. 2003, 278, 28026-28037
38. Carrard, G.; Bulteau, A. L.; Petropoulos, I.; Friguet, B. Impairment of proteasome structure and function in aging Int. J. Biochem. Cell Biol. 2002, 34, 1461-1474
39. Donohue, T. M.; Kharbanda, K. K.; Casey, C. A.; Nanji, A. A. Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease Alcohol.: Clin. Exp. Res. 2004, 28, 1257-1263
40. Fataccioli, V.; Andraud, E.; Gentil, M.; French, S. W.; Rouach, H. Effects of chronic ethanol administration on rat liver proteasome activities: relationship with oxidative stress Hepatology 1999, 29, 14-20
41. Chen, C. K.; Law, W. C.; Aalinkeel, R.; Yu, Y.; Nair, B.; Wu, J.; Mahajan, S.; Reynolds, J. L.; Li, Y.; Lai, C. K.; Tzanakakis, E. S.; Schwartz, S. A.; Prasad, P. N.; Cheng, C. Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells Nanoscale 2014, 6, 1567-1572
42. Tahara, K.; Sakai, T.; Yamamoto, H.; Takeuchi, H.; Hirashima, N.; Kawashima, Y. Improvements in transfection efficiency with chitosan modified poly(DL-lactide-co-glycolide) nanospheres prepared by the emulsion solvent diffusion method, for gene delivery Chem. Pharm. Bull. 2011, 59, 298-301
43. You, J. O.; Liu, Y. C.; Peng, C. A. Efficient gene transfection using chitosan-alginate core-shell nanoparticles Int. J. Nanomed. 2006, 1, 173-180
44. Nafee, N.; Taetz, S.; Schneider, M.; Schaefer, U. F.; Lehr, C. M. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides Nanomedicine 2007, 3, 173-183
45. Liu, X.; Howard, K. A.; Dong, M.; Andersen, M. O.; Rahbek, U. L.; Johnsen, M. G.; Hansen, O. C.; Besenbacher, F.; Kjems, J. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing Biomaterials 2007, 28, 1280-1288
46. Bozkir, A.; Saka, O. M. Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics Drug Delivery 2004, 11, 107-112
47. Katas, H.; Alpar, H. O. Development and characterisation of chitosan nanoparticles for siRNA delivery J. Controlled Release 2006, 115, 216-225
48. Cheng, L.; Jin, C.; Lv, W.; Ding, Q.; Han, X. Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer PLoS One 2011, 6, e25433 10.1371/journal.pone.0025433
49. Xiao, C.; Qi, X.; Maitani, Y.; Nagai, T. Sustained release of cisplatin from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinoma J. Pharm. Sci. 2004, 93, 1718-1724
50. Jagani, H. V.; Josyula, V. R.; Palanimuthu, V. R.; Hariharapura, R. C.; Gang, S. S. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating Eur. J.Pharm. Sci. 2013, 48, 611-618
51. Guo, S.; Huang, L. Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy J. Nanomater. 2011, 2011, 742895 10.1155/2011/742895
52. Shrestha, R.; Elsabahy, M.; Florez-Malaver, S.; Samarajeewa, S.; Wooley, K. L. Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities Biomaterials 2012, 33, 8557-8568
53. Chen, Y.; Bathula, S. R.; Li, J.; Huang, L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer J. Biol. Chem. 2010, 285, 22639-22650
54. Meng, H.; Mai, W. X.; Zhang, H.; Xue, M.; Xia, T.; Lin, S.; Wang, X.; Zhao, Y.; Ji, Z.; Zink, J. I.; Nel, A. E. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo ACS Nano 2013, 7, 994-1005
55. Deng, Z. J.; Morton, S. W.; Ben-Akiva, E.; Dreaden, E. C.; Shopsowitz, K. E.; Hammond, P. T. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment ACS Nano 2013, 7, 9571-9584
56. Zhi, F.; Dong, H.; Jia, X.; Guo, W.; Lu, H.; Yang, Y.; Ju, H.; Zhang, X.; Hu, Y. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro PLoS One 2013, 8, e60034 10.1371/journal.pone.0060034